Guillermo Izquierdo
Overview
Explore the profile of Guillermo Izquierdo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
4734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flores-Cordero J, Aranaz-Murillo A, Vilarino-Garcia T, Perez-Perez A, Izquierdo G, Flores-Campos R, et al.
Neuromolecular Med
. 2025 Feb;
27(1):19.
PMID: 40019662
Obesity, a pandemic health problem, is now considered as a chronic inflammatory state, related to many autoimmune diseases, such as multiple sclerosis. Thus, adipokines, inflammatory mediators secreted by adipose tissue,...
2.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari C, Lo Fermo S, et al.
Neurotherapeutics
. 2025 Feb;
22(2):e00552.
PMID: 39965993
Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated...
3.
Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, et al.
Mult Scler Relat Disord
. 2024 Dec;
93:106185.
PMID: 39662163
Background: The randomized, phase 2 RENEW trial (NCT01721161) evaluated efficacy/safety of opicinumab (anti-LINGO-1) versus placebo in patients with first-episode unilateral acute optic neuritis (AON). Although no significant differences in the...
4.
Cervantes J, Khorsandi J, Patel K, Torrilus C, Izquierdo G, Serota D
Cureus
. 2024 Sep;
16(8):e66609.
PMID: 39258095
Xylazine, commonly referred to as "Tranq," is an alpha-2-adrenergic receptor agonist that is FDA-approved only as a sedative and tranquilizer for veterinary use. However, its use as an adulterant in...
5.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, et al.
PLOS Digit Health
. 2024 Jul;
3(7):e0000533.
PMID: 39052668
Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the...
6.
Campagna M, Kubala Havrdova E, Horakova D, Izquierdo G, Matesanz F, Eichau S, et al.
Mult Scler
. 2024 Mar;
30(9):1216-1220.
PMID: 38511853
Background: The International Multiple Sclerosis Genetics Consortium and MultipleMS Consortium recently reported a genetic variant associated with multiple sclerosis (MS) severity. However, it remains unclear if these variants remain associated...
7.
Signori A, Ponzano M, Kalincik T, Ozakbas S, Horakova D, Kubala Havrdova E, et al.
J Neurol Neurosurg Psychiatry
. 2024 Jan;
95(7):620-625.
PMID: 38242680
Background: To mimic as closely as possible a randomised controlled trial (RCT) and calibrate the real-world evidence (RWE) studies against a known treatment effect would be helpful to understand if...
8.
Dzau W, Sharmin S, Patti F, Izquierdo G, Eichau S, Prat A, et al.
J Neurol Neurosurg Psychiatry
. 2023 Jul;
94(12):984-991.
PMID: 37414538
Background: Whether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We...
9.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sanchez M, Ozakbas S, et al.
Brain
. 2023 Jun;
146(11):4633-4644.
PMID: 37369086
Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle and environmental factors...
10.
Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O, et al.
JAMA Neurol
. 2023 Jun;
80(7):739-748.
PMID: 37273217
Importance: Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of...